References
- SmallGWRabinsPVBarryPPDiagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer’s Association, and the American Geriatrics SocietyJAMA199727816136313719343469
- BerchtoldNCCotmanCWEvolution in the conceptualization of dementia and Alzheimer’s disease: Greco-Roman period to the 1960sNeurobiol Aging19981931731899661992
- Alzheimer’s Disease InternationalWorld Alzheimer Report 2012. Overcoming the Stigma of DementiaLondonAlzheimer’s Disease International2012 Available from: http://www.alz.co.uk/research/WorldAlzheimerReport2012.pdfAccessed November 11, 2014
- BrookmeyerRGraySKawasCProjections of Alzheimer’s disease in the United States and the public health impact of delaying disease onsetAm J Public Health1998889133713429736873
- FrancisPTPalmerAMSnapeMWilcockGKThe cholinergic hypothesis of Alzheimer’s disease: a review of progressJ Neurol Neurosurg Psychiatry199966213714710071091
- GiacobiniEPharmacotherapy of Alzheimer disease: new drugs and novel strategiesProg Brain Res1993984474548248535
- RogersSLFriedhoffLTThe efficacy and safety of donepezil in patients with Alzheimer’s disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study GroupDementia1996762933038915035
- SeltzerBZolnouniPNunezMDonepezil “402” Study GroupEfficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trialArch Neurol200461121852185615596605
- WinbladBKilanderLErikssonSDonepezil in patients with severe Alzheimer’s disease: double-blind, parallel-group, placebo-controlled studyLancet200636795161057106516581404
- RogersSLDoodyRSMohsRCFriedhoffLTDonepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study GroupArch Intern Med19981589102110319588436
- TsunoNDonepezil in the treatment of patients with Alzheimer’s diseaseExpert Rev Neurother20099559159819402770
- RogersSLFarlowMRDoodyRSMohsRFriedhoffLTA 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Donepezil Study GroupNeurology19985011361459443470
- BurnsARossorMHeckerJThe effects of donepezil in Alzheimer’s disease – results from a multinational trialDement Geriatr Cogn Disord199910323724410325453
- ImbimboBPPharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer’s diseaseCNS Drugs200115537539011475943
- JannMWShirleyKLSmallGWClinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitorsClin Pharmacokinet2002411071973912162759
- KurzAFarlowMLefévreGPharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer’s disease: a reviewInt J Clin Pract200963579980519392927
- SozioPCerasaLSMarinelliLDi StefanoATransdermal donepezil on the treatment of Alzheimer’s diseaseNeuropsychiatr Dis Treat2012836136822942647
- PrianoLGascoMRMauroATransdermal treatment options for neurological disorders: impact on the elderlyDrugs Aging200623535737516823990
- ChanALChienYWJin LinSTransdermal delivery of treatment for Alzheimer’s disease: development, clinical performance and future prospectsDrugs Aging200825976177518729547
- MercierFLefévreGHuangHLSchmidliHAmzalBAppel-DingemanseSRivastigmine exposure provided by a transdermal patch versus capsulesCurr Med Res Opin200723123199320418001519
- WinbladBCummingsJAndreasenNA six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer’s disease – rivastigmine patch versus capsuleInt J Geriatr Psychiatry200722545646717380489
- ChoiJChoiMKChongSChungSJShimCKKimDDEffect of fatty acids on the transdermal delivery of donepezil: in vitro and in vivo evaluationInt J Pharm20124221–2839022037444
- iCure. (donepezil patch) [Investigator’s brochure]iCure Pharmaceutical; version 02 Release Date: March 24, 2014
- US Food and Drug Administration, Center for Drug Evaluation and ResearchGuidance for Industry: Skin Irritation and Sensitization Testing of Generic Transdermal Drug ProductsSilver SpringUS Food and Drug Administration1999 Available from: http://www.fda.gov/ohrms/dockets/98fr/990236Gd.pdfAccessed November 18, 2014
- US Food and Drug Administration, Center for Drug Evaluation and ResearchApplication Number 022568 Clinical pharmacology and biopharmaceutics review(s)Silver SpringUS Food and Drug Administration2009 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568orig1s000clinpharmr.pdfAccessed November 20, 2014
- NoetzliMGuidiMEbbingKPopulation pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearanceBr J Clin Pharmacol201478113514424433464
- SeltzerBDonepezil: a reviewExpert Opin Drug Metab Toxicol20051352753616863459